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Smart surface coating of drug nanoparticles
with cross-linkable polyethylene glycol for
bio-responsive and highly eﬃcient drug delivery†
Weijia Wei,a Xiujuan Zhang,*a Xianfeng Chen,b Mengjiao Zhou,a Ruirui Xua and
Xiaohong Zhang*a
Many drug molecules can be directly used as nanomedicine without the requirement of any inorganic or
organic carriers such as silica and liposome nanostructures. This new type of carrier-free drug nano-
particles (NPs) has great potential in clinical treatment because of its ultra-high drug loading capacity and
biodegradability. For practical applications, it is essential for such nanomedicine to possess robust stability
and minimal premature release of therapeutic molecules during circulation in the blood stream. To meet
this requirement, herein, we develop GSH-responsive and crosslinkable amphiphilic polyethylene glycol
(PEG) molecules to modify carrier-free drug NPs. These PEG molecules can be cross-linked on the
surface of the NPs to endow them with greater stability and the cross-link is sensitive to intracellular
environment for bio-responsive drug release. With this elegant design, our experimental results show that
the liberation of DOX from DOX-cross-linked PEG NPs is dramatically slower than that from DOX-non-
cross-linked PEG NPs, and the DOX release proﬁle can be controlled by tuning the concentration of the
reducing agent to break the cross-link between PEG molecules. More importantly, in vivo studies reveal
that the DOX-cross-linked PEG NPs exhibit favorable blood circulation half-life (>4 h) and intense
accumulation in tumor areas, enabling eﬀective anti-cancer therapy. We expect this work will provide a
powerful strategy for stabilizing carrier-free nanomedicines and pave the way to their successful clinical
applications in the future.
Introduction
Cancer is a leading cause of death in all countries and chemo-
therapy has been widely used in combination with other treat-
ments like radiotherapy for curing the disease. However, many
current anticancer drugs suﬀer from serious limitations such
as poor water solubility, rapid blood clearance, widespread
targeting, low accumulation in disease sites, and detrimental
side eﬀects for healthy tissues.1,2 In an attempt to address
these limitations, during the past few decades, many nano-
vehicles have been developed as drug carriers such as
liposomes,3–5 micelles,6–9 polymeric nanoparticles (NPs),10–13
and metal NPs.14–16 These nanovehicles are able to tremen-
dously enhance the water solubility of drugs and increase their
accumulation in tumors via an enhanced permeability and
retention (EPR) eﬀect,2 leading to enhanced eﬃcacy and alle-
viated side eﬀects.17 Although eﬀective, in these strategies, the
carriers do not have a therapeutic function and simply act as a
platform to load and transport drug molecules. In this circum-
stance, these drug carriers are predominantly a major com-
ponent in the drug system and account for a higher weight
portion than actual therapeutics. It apparently leads to a
rather low drug loading capacity (DLC). Even worse, many car-
riers may have potential systemic toxicity when used in the
clinic.18 Recently, pure anticancer therapeutic NPs19–24 have
been developed for a new generation of drug delivery systems,
which generally involve the preparation of one or more pure
hydrophobic drugs into the form of NPs, and then followed by
surface modification with a small amount of surfactants to
realize water dispersity and bioenvironmental stability for
eﬃcient drug delivery. Such a drug delivery system can sub-
stantially boost drug loading capacity and avoid the risk of
any unnecessary burden to patients. Nevertheless, this type of
drug NPs possess inadequate in vivo stability, since the surfac-
tant is anchored to the surface of NPs only through weak
hydrophobic interactions. The lack of stability may result in
premature drug release following administration into the
blood stream.
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c5nr09167e
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Herein, in this work, we have synthesized two bio-respon-
sive and crosslinkable amphipathic surfactants which can
eﬃciently minimize any premature drug release from drug
NPs during blood circulation and achieve bio-responsive
release at the tumor site. Considering that the intracellular
concentration of glutathione (GSH) is considerably greater
than that in the extracellular environment (∼10 mM vs.
∼2 μM),25 we developed two types of GSH-responsive molecules
including PEG5000-Lys-LA2 (PEGA) and PEG
5000-Lys-(Lys-LA2)2
(PEGB). Then they were applied in the surface functionali-
zation of doxorubicin (DOX) NPs for controlled intracellular
drug release. The stability, in vitro drug release, cytotoxicity,
cellular uptake, blood circulation, biodistribution, and anti-
tumor activity were systematically studied for diﬀerent types of
NPs including bare DOX NPs, DOX NPs coated with PEGA and
PEGB (individually termed as DOX-NCLPEGA NPs and
DOX-NCLPEGB NPs), as well as DOX NPs coated with cross-
linked surfactant molecules (termed DOX-CLPEGA NPs and
DOX-CLPEGB NPs). Compared with other NPs, the cross-linked
surfactant modified DOX NPs show much better bio-stability,
longer blood circulation time, and promoted drug delivery to
tumor sites as a result of the adequately inhibited premature
release of payload molecules. This is the first report in which
crosslinkable polymer molecules are applied to modify pure
drug nanoparticles for improved stability and intracellular
environment responsive release. This type of pure drug nano-
medicine will have a great potential for clinical applications as
it does not contain an extra drug carrier material and is less
toxic. We conceive the experimental findings to be of great
importance to guide the preparation and application of
carrier-free nanomedicines in research and future clinical
settings.
Results and discussion
Synthesis and characterization of PEG5000-Lys-(Lys-LA2)2 and
PEG5000-Lys-LA2
To exhibit an excellent performance, the amphiphilic ligand
molecules should include hydrophilic, hydrophobic and cross-
linkable segments. The ratio of hydrophilic segments to hydro-
phobic and crosslinkable segments is a key factor. Herein, two
types of novel ligand, PEG5000-Lys-(Lys-LA2)2 and PEG
5000-Lys-
LA2, containing hydrophobic and crosslinkable lipoic acid (LA)
and hydrophilic PEG were synthesized. The synthetic route of
PEG5000-Lys-(Lys-LA2)2 is depicted in Scheme 1. The
1H NMR
spectrum of PEG5000-Lys-(Lys-LA2)2 (Fig. 1a) displays signals at
1.85–1.90, 3.51, and 3.69 ppm, attributed to the hydrogen
protons in LA, PEG backbone and lysine (Lys), respectively.26,27
In addition, the molecular weight of PEG5000-Lys-(Lys-LA2)2 in
MALDI-TOF Mass Spectrometry (Fig. S4†) was almost identical
to the theoretical value comparing it to the starting PEG-NH2.
Preparation and characterization of DOX NPs
DOX NPs were synthesized by a solvent exchange method. As
Scheme 2 shows, doxorubicin hydrochloride (DOX·HCl) is
firstly converted to being hydrophobic. To achieve this, HCl is
removed from the molecule by adding triethylamine (TEA) to
DOX·HCl in dimethyl sulfoxide (DMSO) solution in a basic
environment. Then the DOX/DMSO solution was injected
Scheme 1 Synthetic route of PEG5000-Lys-(Lys-LA2)2.
Fig. 1 (a) 1H NMR spectrum of PEG5000-Lys-(Lys-LA2)2. (b) SEM and
TEM (inset) images of bare DOX NPs. (c) The evolution of the sizes of
diﬀerent NPs over a period of 3 days.
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dropwise into water under vigorous stirring to obtain DOX
NPs. Subsequently, a solution of PEGB was injected into the
bare DOX NPs suspension to obtain the NPs with non-cross-
linked ligands on their surface. To improve the stability of
NPs, the surfactant molecules were cross-linked on the surface
of NPs by adding dithiothreitol (DTT) to the solution contain-
ing DOX NPs and PEGB under nitrogen. The formation of the
cross-link between surfactant molecules can be demonstrated
by the apparent change of the absorbance at 330 nm in the
UV-Vis absorption spectra of the non-cross-linked PEG5000-Lys-
(Lys-LA2)2 and cross-linked PEG
5000-Lys-(Lys-LA2)2 (Fig. S5†).
26
SEM and TEM images of bare DOX NPs are presented
in Fig. 1b. These NPs are mostly spherical and the size is
relatively uniform. Dynamic light scattering (DLS) measure-
ment (Fig. S6†) reveals that the average size of these DOX NPs
is about 100 nm. After surface modification with PEGB, the
size of the NPs does not change much no matter whether the
ligand molecules are cross-linked or not. The stability of these
NPs in phosphate buﬀered saline (PBS) is shown in Fig. 1c.
Apparently, PEGB modified NPs are very stable. During the
observation period of 3 days, the size of the surface coated NPs
increased only slightly. In great contrast, the bare DOX NPs
have poor stability, demonstrated by the dramatic size increase
during the same observation time window. Apparently, almost
all of the uncoated NPs have aggregated. For the NPs coated
with cross-linked PEGB on the surface, even when we add
10 mM DTT into the solution to break the cross-link, they still
remain relatively stable.
Release profiles of DOX from various types of NPs
To understand the influence of the surface modification of
DOX NPs on their release profiles, we performed a study by
placing various types of NPs in dialysis containers and measur-
ing the release of DOX. In the investigation, we studied three
types of DOX NPs including DOX-C18PMH-PEG NPs,
DOX-NCLPEGB NPs and DOX-CLPEGB NPs. The results are pre-
sented in Fig. 2. For the groups of DOX-NCLPEGA NPs and
DOX-CLPEGA NPs, the results are displayed in Fig. S7.† For
DOX-C18PMH-PEG NPs, DOX is rapidly released and about
70% of DOX is released within the first 10 h. For
DOX-NCLPEGB NPs, although the release of DOX is slightly
slower, the diﬀerence is rather small. Within the same period
of the first 10 h, the release only slightly decreases from about
70% to 65%. In a stark contrast, the release of DOX from
DOX-CLPEGB NPs is dramatically alleviated. For the same
period of time, only about 15% of DOX has been liberated.
Compared to DOX-CLPEGB NPs, the release of DOX from the
DOX-CLPEGA NPs is slightly higher. About 23% of DOX is
released within the same period (Fig. S7b†). The diﬀerent
release profiles between DOX-CLPEGA NPs and DOX-CLPEGB
NPs may be ascribed to the amount of the LA group in the
ligands. PEGB contains double number of the LA group in
Scheme 2 Schematic illustration of DOX NPs coated by PEG5000-Lys-
(Lys-LA2)2.
Fig. 2 The release proﬁles of DOX from diﬀerent types of NPs and under diﬀerent conditions. (a) The release proﬁles of DOX from
DOX-C18PMH-PEG NPs, DOX-NCLPEGB NPs and DOX-CLPEGB NPs. (b) The release proﬁles of DOX-CLPEGB NPs in the presence of diﬀerent con-
centrations of DTT in PBS. (c) The release proﬁles of DOX-NCLPEGB NPs and DOX-CLPEGB NPs. For the DOX-CLPEGB NPs, the release was in PBS
for the ﬁrst 5 h. After 5 h, 10 mM DTT was added to the solution.
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comparison with PEGA, which leads to double cross-linked
disulfide bonds in the DOX-CLPEGB NPs.
To demonstrate that the improved retention of DOX within
the DOX-CLPEGB and DOX-CLPEGA NPs is due to the cross-
linked ligand molecules, we purposely added 10 mM DTT into
the solution to break the cross-linking. This amount of DTT is
similar to the level of intracellular GSH. Expectedly, the release
of DOX from the NPs sharply increases and the profile is
almost the same as that of the NPs without cross-linked PEG
molecules on the surface (Fig. 2a). In consideration of the
release profile of DOX from NPs, PEGB seems a very suitable
surfactant and can be used to modify nanomedicines for
improved blood circulation stability.
When the DTT concentration in dialyzed media is the same
as the extracellular level of GSH (2 μM), the release profile
from the DOX-CLPEGB NPs is similar to that in the release
media without DTT (Fig. 2b). Notably, the DOX release is
gradually promoted as the DTT concentration increases from
2 μM to 1 and 10 mM. This means that the release of drug
molecules will only be boosted when the nanomedicine is
internalized by cells. This characteristic is very useful in drug
delivery.
To further demonstrate that the drug release can be con-
veniently controlled, we incubated DOX-NCLPEGB NPs and
DOX-CLPEGB in PBS. For DOX-CLPEGB NPs, after 5 hours
incubation, 10 mM DTT was added to the solution. The results
are shown in Fig. 2c. It is obvious that there is a burst of drug
release from the NPs with cross-linked PEG5000-Lys-(Lys-LA2)2
once 10 mM was added. After the burst release of DOX from
the NPs with cross-linked surfactant molecules, the sub-
sequent release profiles (after 9 h incubation) of both types of
NPs are nearly identical. Overall, as shown in these release pro-
files, for NPs modified with cross-linked PEG molecules, the
premature drug release during circulation can be eﬃciently
inhibited. Also attractively, the release of therapeutic mole-
cules from these NPs is potentially controllable by both intra-
cellular and extracellular environments.
In vitro cellular uptake and cell imaging
The intracellular uptake of DOX-NCLPEGB NPs and
DOX-CLPEGB NPs was investigated in human cervical cancer
(HeLa) cells by using confocal microscopy. Free DOX·HCl
molecules were used as a control group. As shown in Fig. 3a,
the HeLa cells treated with DOX·HCl for 6 h exhibit more
intense fluorescence signals than the two types of NPs. The
variation is due to the diﬀerent internalization mechanisms of
free DOX and DOX NPs. Briefly, DOX·HCl molecules enter cells
through diﬀusion and then diﬀuse further into the nuclei,
while NPs are internalized by endocytosis.28–30 Moreover, we
can see that the HeLa cells treated with DOX-CLPEGB NPs
possess stronger fluorescence intensity than those incubated
with DOX-NCLPEGB NPs.
26 The finding is similar for the cells
with incubation time of both 6 and 12 h with the NPs. The cel-
lular uptake was also quantitatively studied by flow cytometry
analysis and the results are in agreement with the above find-
ings. As shown in Fig. 3f and g, a much greater amount of
DOX·HCl is internalized in HeLa cells, when compared with
both types of DOX NPs. Additionally, the cells incubated with
DOX-CLPEGB NPs display more intense fluorescence signals
than those treated with DOX-NCLPEGB NPs.
In vitro cytotoxicity of DOX NPs
In vitro cytotoxicity of DOX NPs was assessed with two types of
tumor cell lines including mouse metastatic breast cancer cell
line (4T1), and HeLa cell line, as well as one type of normal
cells, human hepatocytes (HL-7702). In the experiment,
DOX·HCl, DOX-NCLPEGB NPs and DOX-CLPEGB NPs were cul-
tured with all cell lines at diﬀerent concentrations ranging
from 1.25 to 20 μg mL−1 (1.25, 2.5, 5, 10 and 20 μg mL−1) for
24 and 48 h. As presented in Fig. 4a and b, all samples show
time and dose dependent cytotoxicity to 4T1 cells. At all con-
centrations, DOX NPs possess low toxicity than free DOX mole-
cules. For example, after 24 h incubation, at the highest drug
concentration of 20 μg mL−1, DOX·HCl exhibits higher cyto-
toxicity (viability of 23%) than both groups of DOX NPs (viabil-
ities of about 30–40%). This is possibly due to the delayed
release of DOX molecules from the NPs inside the cells,
while free DOX molecules can easily diﬀuse through passive
diﬀusion. Meanwhile, as illustrated in Fig. 4c and d, in normal
cell line, two types of DOX NPs exhibit dramatically lower cyto-
toxicity than DOX·HCl. This may be attributed to the high pH
and low intracellular GSH concentration in normal cell line in
comparison with those in cancer cells.
In vivo blood circulation and biodistribution of DOX NPs
To study whether the cross-link strategy can be applied for
inhibiting premature drug release during blood circulation, we
intravenously injected DOX-NCLPEGB NPs and DOX-CLPEGB
Fig. 3 (a) Intracellular distribution of DOX·HCl in HeLa cells after 6 h
incubation. (b, c) Intracellular distribution of DOX-NCLPEGB NPs and
DOX-CLPEGB NPs in HeLa cells after 6 h incubation, (d, e) Intracellular
distribution of DOX-NCLPEGB NPs and DOX-CLPEGB NPs in HeLa cells
after 12 h incubation. Scale bars: 40 μm. (f, g) Flow cytometry analysis of
DOX·HCl, DOX-NCLPEGB NPs and DOX-CLPEGB NPs in HeLa cells after
6 h and 12 h incubation.
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NPs into diﬀerent groups of BALB/c mice. Blood samples were
collected at diﬀerent time points after injection. The mice
administered with DOX-C18PMH-PEG NPs were adopted as a
control. The fluorescence intensity of each blood sample was
recorded and calibrated and the results are presented in
Fig. 5a and these indicate that the blood circulation half-life of
the DOX-CLPEGB NPs is much longer (>4 h) than those of the
other two types of NPs (∼3 h). This indicates that cross-linking
surfactant molecules is able to better encapsulate the nano-
medicine and enable longer blood circulation time. In other
words, the premature release of drug molecules from the nano-
medicine can be eﬀectively inhibited.
In vivo biodistribution study was also carried out. Diﬀerent
DOX NPs were intravenously injected into 4T1 tumor bearing
mice, and then the fluorescence intensities of DOX in various
organs were monitored at diﬀerent time intervals. Fig. 5b
shows the biodistribution of DOX in major visceral organs and
tumors of the mice treated with the DOX-NCLPEGB NPs or
DOX-CLPEGB NPs at 24 h post injection. The results clearly
demonstrate that the tumors of the mice treated with the
DOX-CLPEGB NPs possess higher levels of DOX. Collectively,
all of these outcomes suggest that the cross-link strategy works
eﬃciently and have inhibited premature drug release during
circulation. This leads to improved delivery of drug molecules
to the tumor sites.
In vivo anticancer activities
To investigate the in vivo therapeutic eﬃcacy of the DOX NPs,
we chose 4T1 tumor bearing BALB/c mice as an animal model.
For tumor treatment, PBS and DOX·HCl, DOX-NCLPEGB NPs
and DOX-CLPEGB NPs containing 1 mg ml
−1 of DOX were
intravenously administered in diﬀerent groups of mice. The
same treatment was repeated at 7 days after the primary injec-
tion. The tumor size and body weight of each mouse were
recorded daily for two weeks to quantitatively evaluate the anti-
tumor eﬃcacy. As shown in Fig. 6a, the DOX NPs adequately
inhibit the growth of tumor and the therapeutic eﬃcacy is
certainly better than the free DOX molecules. Particularly, the
DOX-CLPEGB NPs realize a treatment eﬃcacy (the tumor
volume is 1.86 ± 0.41 fold of the initial value), which is clearly
better than DOX-NCLPEGB NPs (2.90 ± 0.49 fold), DOX·HCl
(4.92 ± 0.51 fold) and the PBS (7.35 ± 0.66 fold).
Meanwhile, the mice treated with DOX NPs maintain a
steady body weight to a certain extent (Fig. 6b). However, the
mice which received injection of DOX·HCl experience a drop
in body weight probably due to its serious side eﬀect. Appar-
ently, compared with DOX·HCl, the DOX-CLPEGB NPs can
achieve greatly enhanced therapeutic eﬃciency with alleviated
side eﬀects.
Experimental
Materials
DOX·HCl (99%, Beijing ZhongShuo Pharmaceutical Techno-
logy Development Co., Ltd), 3-(4,5-dimethyl-2-thiazolyl)-2,5-
Fig. 5 (a) Blood circulation curve of DOX-C18PMH-PEG NPs,
DOX-NCLPEGB NPs and DOX-CLPEGB NPs, which was obtained
through recording the ﬂuorescence intensities of DOX in the blood at
various times after drug administration. The unit is the percentage of the
injected dose per gram tissue (% ID g−1). (b) Biodistribution of
DOX-NCLPEGB NPs and DOX-CLPEGB NPs determined by measuring
the ﬂuorescence intensities of DOX in major organs and tumor tissues
in vivo at 24 h after injection.
Fig. 4 (a) and (b) Cell viabilities of 4T1 cell lines after being incubated
with DOX·HCl, DOX-NCLPEGB NPs and DOX-CLPEGB NPs for 24 and
48 h, respectively. (c) and (d) Cell viabilities of HL-7702 cell lines after
being incubated with DOX·HCl, DOX-NCLPEGB NPs and DOX-CLPEGB
NPs for 24 and 48 h, respectively.
Fig. 6 In vivo anticancer eﬀect of free DOX, DOX-NCLPEGB NPs and
DOX-CLPEGB NPs. (a) The evolution of the tumor volume with time
after the mice were administered with saline, free DOX and
DOX-NCLPEGB NPs and DOX-CLPEGB NPs. Each formulation was
injected on Day 0 and 7, and the injection concentration was 1 mg mL−1.
(b) Body weight changes with time of 4T1 tumor bearing mice during
the treatment period.
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diphenyl-2-H-tetrazolium bromide (MTT), di-Boc-lysine, DTT
and LA (J&K Scientific Ltd) were used as received. Dimethyl
sulfoxide-d6 (DMSO-d6), 1-ethyl-3-(3-dimethylaminopropyl) carbo-
diimide hydrochloride (EDC), and 4-dimethylaminopyridine
(DMAP) were from J&K Scientific Ltd TEA, DMSO, ethanol,
ether, trifluoroacetic acid (TFA) and dichloromethane (DCM)
were ordered from Sinopharm Chemical Reagent Co., Ltd.
Monomethoxy poly(ethylene glycol) (MePEG-NH2, MW =
5 kDa, purity >95%) was from Shanghai Yare Biotech, Inc. All
reagents and solvents were of analytical grade.
Characterization
1H NMR spectra were obtained from a Unity Inova 400 spectro-
meter operating at 400 MHz using DMSO-d6 as a solvent. The
chemical shifts were calibrated against residual solvent
signals. The mass spectra were collected on a ABI 4700 MALDI-
TOF/TOF mass spectrometer (linear mode) using trans-2-[3-(4-
tert-butylphenyl)-2-methyl-2-propenylidene] malononitrile as a
matrix. UV-Vis absorption spectra were recorded on a Perkin-
Elmer Lambda 750 UV/Vis/NIR Spectrophotometer. The fluo-
rescence spectra were recorded with a FluoroMax 4 (Horiba
Jobin Yvon) Spectrofluorometer. Scanning electron micro-
scopic (SEM) images were collected on a FEI Quanta 200 FEG
field emission scanning electron microscope. Transmission
electron microscopy (TEM) images were observed using a
Tecnai G220. DLS analysis measurements were recorded using
a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK).
Cell culture
HeLa cells were cultured in Dulbecco’s Modified Eagle’s
medium (DMEM) and HL-7702 and 4T1 cells were cultured in
Roswell Park Memorial Institute (RPMI) 1640 medium. The
culture media contain 10% of fetal bovine serum (FBS) and
antibiotics including penicillin and streptomycin with 50 units
per milliliter at 37 °C under a humidified atmosphere contain-
ing 5% CO2.
Synthesis of PEG5000-Lys-LA2 and PEG
5000-Lys-(Lys-LA2)2
Di-Boc-lysine (1.5 eq.) was dissolved in CH2Cl2, mixed with
EDC·HCl (1.8 eq.), DMAP (1.8 eq.) and TEA (2 eq.) and acti-
vated at 37 °C for 4 h. This is followed by mixing with PEG5000-
NH2 (1 eq.), and stirring at room temperature for 24 h. Then
the solution was mixed with ice-cold ether. Subsequently, the
precipitate was filtered and washed with cold ethanol and
ether to obtain purified di-Boc-lysine-PEG5000. The obtained
PEG derivative ester was dissolved in CH2Cl2/TFA (1 : 1, v/v)
and stirred for 2 h at room temperature. Finally, the solvent
was discarded and the product was precipitated in cold ether,
and washed with cold ethanol and ether.
LA (3 eq.), EDC·HCl (3.6 eq.), DMAP (3.6 eq.) and TEA
(4 eq.) were dissolved in CH2Cl2 and activated at 37 °C for 4 h,
followed by mixing with di-NH2-lysine-PEG
5000 (1 eq.). The
reaction lasted for 24 h at room temperature under rigorous
stirring. The solution was then added into 10-fold volume of
cold ethyl ether to precipitate the PEG5000-Lys-LA2, followed by
three washes with cold ethanol and ether.
The NH2-terminated PEG
5000-lysine (1 eq.) was conjugated
with di-Boc-lysine (3 eq.) that was pre-activated with EDC·HCl
(3.6 eq.), DMAP (3.6 eq.) and TEA (4 eq.) at 37 °C for 4 h. The
conjugating reaction was stirred for 24 h at room temperature.
After filtration and precipitation, the obtained PEG5000-Lys-
(di-Boc-lysine)2 was treated with CH2Cl2/TFA (1 : 1, v/v) as
described formerly. Then the PEG5000-Lys-(Lys-LA2)2 was
synthesized with the same procedures as described above by
conjugating NH2-terminated PEG
5000-Lys-(Lys)2 (1 eq.) with
pre-activated LA (6 eq.).
Preparation and modification of DOX NPs
First, 10 mL of 2 mg mL−1 DOX·HCl/DMSO solution was pre-
pared and then 12 μL of TEA (1.5 eq.) was added under a mod-
erate stirring at 25 °C. Through this step, hydrophilic DOX·HCl
molecules were converted to being hydrophobic. Subsequently,
DOX NPs were synthesized by a dropwise injection of 200 µL of
the above prepared hydrophobic DOX in DMSO into 10 mL of
water under robust stirring and then the stirring was contin-
ued for 5 min. Finally, 400 µL of 1.0 mg mL−1 PEGA and PEGB
aqueous solutions were individually added to two solutions of
10 mL of bare DOX NPs. The mixtures were then ultrasoni-
cated for 5 min followed by 1 h incubation at room tempera-
ture to obtain PEGA and PEGB modified DOX NPs.
Preparation of DOX-CLPEG NPs
The pH of the above-prepared NPs solution was adjusted to be
8.5 using 0.7 M borate buﬀer (pH 9.0), and the dispersion was
purged with nitrogen for 10 min. The cross-linking of the
ligand molecules on the surface of NPs was achieved through
the addition of 10 mol% DTT relative to the quantity of the
lipoyl units in the surfactant. Subsequently, the solution was
stirred under nitrogen for 22 h at room temperature.
Stability of NPs in PBS
The stability study was performed to monitor the evolution of
the size distribution of bare DOX NPs, DOX-NCLPEGA NPs,
DOX-NCLPEGB NPs, DOX-CLPEGA NPs and DOX-CLPEGB NPs
in PBS.
In vitro release of DOX
The DOX NPs modified by C18PMH-PEG were used as a refer-
ence for comparison. The C18PMH-PEG was synthesized as
described in our previously published paper.20 Solutions of
2 mL of DOX-C18PMH-PEG NPs, DOX-NCLPEGA NPs and
DOX-CLPEGA NPs (2 samples) were injected into separate
dialysis cartridges with a 14 kDa MWCO. These cartridges
were individually dialyzed against 100 mL PBS at 37 °C except
that one cartridge containing DOX-CLPEGA NPs was dialyzed
in 100 mL PBS with 10 mM DTT. At desired time intervals,
1 mL solution was collected from each sample for fluorescence
measurement and the dialysis medium was replenished with
an equal volume of fresh one. In a separate experiment, car-
tridges containing DOX-CLPEGA NPs solution were individu-
ally dialyzed against PBS with various DTT concentrations
(0, 2 μM and 1 mM) at 37 °C. In another experiment, DTT
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(10 mM) was added to the release medium at 5 h after starting
dialysis. For the other group of DOX-NCLPEGB NPs and
DOX-CLPEGB NPs, the experimental design was the same as
the above.
The quantity analysis of DOX release was performed
through the measurement of its fluorescence intensity by a
FluoroMax 4 (Horiba Jobin Yvon) spectrofluorimeter (exci-
tation at 488 nm). The fluorescence spectra of DOX of diﬀerent
solutions were recorded from 520 to 650 nm. The experiments
were performed in triplicate and the average was presented for
analysis.
In vitro cytotoxicity of NPs
Eighty µL of complete media with HeLa, 4T1, HL-7702 cells
were placed into diﬀerent 96-well plates (∼60 000 per well)
followed by incubation of 24 h. Next, 20 µL of DOX NPs in PBS
of diﬀerent concentrations were added to each well for incu-
bation (37 °C, 5% CO2). The concentrations of NPs were 1.25,
2.5, 5, 10 and 20 μg mL−1 in diﬀerent groups. After the
addition of DOX NPs, the cells were further incubated for 24
and 48 h, followed by being treated with 20 µL of MTT solution
(5 mg mL−1 in PBS) for 4.5 h for a standard MTT assay
measurement.
In vitro cellular uptake of DOX and DOX NPs
Flow cytometry (FCM) and confocal laser scanning microscopy
(CLSM) were performed to study the cellular uptake of the
DOX·HCl, DOX-NCLPEGB NPs and DOX-CLPEGB NPs. For ana-
lysis, HeLa cells were cultured with diﬀerent DOX materials for
6 h and then washed with PBS three times. Following this, the
cells were fixed with 4% formaldehyde for 5 min followed by
another 3 times of washing in PBS. The cell nuclei were
stained with 4′,6-diamidino-2-phenylindole (DAPI, blue) for
10 min. Then the cells were washed with PBS three times for
subsequent confocal fluorescence microscopy imaging using a
Leica laser scanning confocal microscope. For FCM, the cells
were seeded in 12-well plates (∼12 000 cells per well). After
incubation, the cells were collected by trypsin and centrifuged
at 1000 rpm for 3 min. This process was repeated three times
and the cells were washed with fresh PBS. Finally, the cells
suspended in DMEM media were analyzed for fluorescence
intensity with a flow cytometer (BD Biosciences, USA).
In vivo blood circulation and biodistribution of NPs
All in vivo experiments were performed in compliance with the
relevant laws and institutional guidelines and also approved
by Laboratory Animal Center of Soochow University. Diﬀerent
groups of BALB/c mice were administered with 200 µL
of 1 mg mL−1 DOX-NCLPEGB NPs, DOX-CLPEGB NPs, and
DOX-C18PMH-PEG NPs. The circulation of NPs was investi-
gated by measuring the fluorescence intensity of DOX at
560 nm in each blood sample. For the measurement, approxi-
mately 10 µL of blood was collected from the tail vein of each
mouse at desired time intervals (0.25, 0.5, 1, 2, 4, 6, 12 and
24 h). Each blood sample was dissolved in 1 mL of lysis buﬀer
(1% SDS, 1% Triton X-100, 40 mM Tris acetate). The fluo-
rescence intensities of DOX NPs with a series of concen-
trations were recorded for a standard calibration curve. This
experiment was also run in triplicate and the average results
were adopted for analysis.
For the analysis of the biodistribution of NPs, 4T1 tumor
bearing mice were injected with solution containing either
DOX-NCLPEGB NPs or DOX-CLPEGB NPs via a tail vein. The
dose was 1 mg mL−1. At specific time intervals including 2, 6,
12 and 24 h, the mice were sacrificed. The fluorescence
intensities of a number of organs and tissues including liver,
spleen, heart, lung, kidney, stomach, intestine, skin and
tumors were recorded by the Maestro system. The results were
calibrated by subtracting the autofluorescence of individual
tissues and organs as well as the background reading using
the untreated mouse as a reference group for a semi-quanti-
tative biodistribution analysis.
In vivo antitumor activity
Five to six weeks old female BALB/c mice were raised to develo-
ped therapy models for solid tumor by implanting 4T1 cells
into the right backside. After 6 days, the volumes of the
tumors were estimated to be about 55–90 mm3. The value was
calculated by the equation of volume = a × b2/2 in which a and
b represent the longest and shortest diameters of a tumor.
Subsequently, the mice were divided into 4 groups (n = 6) in a
random manner. Subsequently, one mg mL−1 of DOX·HCl,
DOX-NCLPEGB NPs, DOX-CLPEGB NPs or PBS solution was
administered to the diﬀerent groups of mice via a tail vein
injection. The same treatment was repeated at 7 days after the
primary injection. The tumor size and body weight of each
individual mouse were recorded daily for two weeks.
Conclusion
In summary, we designed and synthesized a GSH-responsive
and crosslinkable amphipathic surfactant, PEG-Lys-(Lys-LA2)2,
and applied it to modify carrier-free DOX NPs with a cross-
linking structure. The release of DOX from NPs with cross-
linked PEG-Lys-(Lys-LA2)2 molecules is significantly slower
than that from the ones with non-cross-linked ligand coating.
This indicates that the problem of premature drug release
from carrier-free nanomedicine can be eﬃcaciously solved
with surface coating of cross-linked surfactant molecules. In
the meantime, for the DOX NPs with cross-linked surface
molecules, bio-responsive drug release and eﬃcient intracellu-
lar uptake can be achieved. In vivo studies show that the DOX
NPs coated with cross-linked ligands exhibit favorable blood
circulation half-life (>4 h), intense accumulation in the tumor
area and potent anticancer eﬃcacy. This work further paves a
way of using carrier-free nanomedicines for powerful drug
delivery in clinical applications.
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